Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Novartis Sues Intas Over Patent Infringement Claims

Novartis AG sued Intas Pharmaceuticals Ltd. for patent infringement, claiming it sought U.S. approval to sell a generic version of the immunosuppressant drug Myfortic before Novartis’s patents expired.

Novartis, in a filing today in federal court in Washington, seeks to block Intas and its U.S. unit, Accord Healthcare Inc., from importing and selling generic Myfortic in the U.S. until its patents expire April 2017.

Novartis, based in Basel, Switzerland, alleges its patents were violated when Intas filed a new drug application with the U.S. Food and Drug Administration seeking to manufacture and sell 180 milligram delayed-release tablets of generic Myfortic, claiming Novartis’s patents are invalid.

The medication is used to treat patients who have had kidney transplants.

“Defendants products, if approved, will be administered to human patients in an amount effective to immunosuppress those patients, which administration constitutes direct infringement,” Frederick Haughey, a lawyer for Novartis, wrote in the complaint.

Chid Iyer, a lawyer for Ahmedabad, India-based Intas Pharmaceuticals at Sughrue Mion Pllc in Washington, didn’t immediately respond to an e-mail message seeking comment on the lawsuit.

The case is Novartis AG v. Accord Healthcare Inc. USA, 13-cv-01013, U.S. District Court, District of Columbia (Washington).

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.